Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 31, 2020Biomedicine & PharmacotherapyOpen Access

Protective effects of AS-IV on diabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DM

View Full Paper
Ask AI
Bookmark
Share

Key result

Astragaloside IV (AS-IV) improved cardiac function, ameliorated histopathological changes, and reduced myocardial inflammation and fibrosis in T2DM rats over 8 weeks.

Why the study?

To investigate whether Astragaloside IV could prevent T2DM-induced cardiomyopathy and regulate abnormal myocardial lipid metabolism in diabetes.

Does Astragaloside IV (AS-IV) improve cardiac function and myocardial lipid metabolism in rat models of T2DM?

Population

High-fat diet and low-dose STZ-induced T2DM model rats

Comparison

AS-IV vs metformin

Design

Animal experimental study

Follow-up

8 weeks

Authors

ZWZhongyuan WangNanjing Agricultural UniversityYZYunfeng ZhuAnhui Medical UniversityJZJie ZhangAerospace Center Hospital

Discussion

Loading...

Member takes

Overview

AS-IV merits further study in diabetic cardiomyopathy models; leaves open any role in human T2DM management.

Key Points

  • To evaluate whether astragaloside IV (AS-IV) prevents diabetic cardiomyopathy and improves disordered myocardial lipid metabolism in a rat model of type 2 diabetes mellitus.
  • Induced type 2 diabetes mellitus (T2DM) in rats using a high-fat diet combined with a low-dose streptozotocin (STZ) injection.
  • Treated diabetic model rats and high-fat diet controls with astragaloside IV (AS-IV) or metformin for 8 weeks.
  • AS-IV significantly improved cardiac systolic and diastolic function and ameliorated histopathological myocardial injury in T2DM rats.
  • Treatment improved circulating lipid profiles (TC, TG, and HDL levels) and reduced myocardial lipid accumulation in both T2DM and high-fat diet models.
  • AS-IV significantly suppressed myocardial fibrosis and the expression of inflammatory cytokines, including TNF-α, IL-6, and IL-1β.

Structured PICO

Does Astragaloside IV (AS-IV) improve cardiac function and myocardial lipid metabolism in rat models of T2DM?

P
Population
Rat models of T2DM induced by high-fat diet and low-dose STZ treated with AS-IV and metformin for 8 weeks.
I
Intervention
Astragaloside IV (AS-IV) and metformin (Met) for 8 weeks
O
Outcome
Cardiac systolic and diastolic function, and cardiac histopathological changessurrogate

Astragaloside IV shows protective effects against T2DM-induced myocardial injury in rats, likely by improving lipid metabolism and reducing inflammation.

Cite This Study

Wang et al. (2020) studied Diabetic cardiomyopathy. Astragaloside IV (AS-IV) vs. Metformin (Met) and untreated T2DM rats was evaluated on Cardiac systolic and diastolic function, cardiac histopathological changes, and lipid metabolism. Astragaloside IV (AS-IV) improved cardiac function, ameliorated histopathological changes, and reduced myocardial inflammation and fibrosis in T2DM rats over 8 weeks.

synapsesocial.com/papers/6a857ff6a46f793aa75e288ehttps://doi.org/10.1016/j.biopha.2020.110081
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Cardiac metabolism in a new rat model of type 2 diabetes using high-fat diet with low dose streptozotocin2013 · 147 citations
  2. 2Tumor Necrosis Factor-α Mediates Cardiac Remodeling and Ventricular Dysfunction After Pressure Overload State2007 · 386 citations
  3. 3CCN5 knockout mice exhibit lipotoxic cardiomyopathy with mild obesity and diabetes2018 · 23 citations
  4. 4Protective Effect of Astragaloside IV on Hepatic Injury Induced by Iron Overload2019 · 25 citations